Energy deficit in Huntington disease: why it matters

Fanny Mochel, Ronald G. Haller


Huntington disease (HD) is an autosomal dominant neurodegenerative disease with complete penetrance. Although the understanding of the cellular mechanisms that drive neurodegeneration in HD and account for the characteristic pattern of neuronal vulnerability is incomplete, defects in energy metabolism, particularly mitochondrial function, represent a common thread in studies of HD pathogenesis in humans and animal models. Here we review the clinical, biochemical, and molecular evidence of an energy deficit in HD and discuss the mechanisms underlying mitochondrial and related alterations.

Find the latest version:

http://jci.me/45691-pdf
Huntington disease (HD) is an autosomal dominant neurodegenerative disease with complete penetrance. Although the understanding of the cellular mechanisms that drive neurodegeneration in HD and account for the characteristic pattern of neuronal vulnerability is incomplete, defects in energy metabolism, particularly mitochondrial function, represent a common thread in studies of HD pathogenesis in humans and animal models. Here we review the clinical, biochemical, and molecular evidence of an energy deficit in HD and discuss the mechanisms underlying mitochondrial and related alterations.

Introduction
Huntington disease (HD) is an autosomal dominant neurodegenerative disease with age-dependent complete penetrance. HD is caused by a CAG repeat expansion in the first exon of the HTT gene that encodes huntingtin (Htt) (1, 2). Individuals who have 36 CAG repeats or more may develop the clinical symptoms and signs of HD, including neuropsychiatric, motor, and cognitive abnormalities that cause a progressive loss of functional capacity and shortened life span. The clinical features of HD typically emerge in adulthood between 30 and 50 years of age, after which the disease progresses relentlessly over the next 15–20 years (3). Presymptomatic testing — preceded by genetic counseling according to internationally accepted guidelines — allows at-risk persons to assess whether they carry the gene mutation and thus predict whether a carrier will develop HD before he or she shows clinical symptoms and signs. Of importance, the presymptomatic phase in HD provides a unique window for therapeutic intervention and neuroprotection.

γ-Aminobutyric acid (GABAergic) medium spiny neurons of the striatum that contain enkephalin or substance P and project to the globus pallidus and substantia nigra are particularly vulnerable in HD and are key to the characteristic involuntary movements in this disease (4). The basis of the selective vulnerability of these neurons in HD remains elusive but may involve the reduced phosphorylation of Htt at serine 421 in the striatum (5), the specific localization of Rhes (Ras homolog enriched in striatum; a small guanine nucleotide–binding protein partner of Htt) to the striatum (6), and/or the preferential vulnerability of the striatum to mitochondrial dysfunction (7). However, the neuropathology is ultimately more widespread, affecting cortical neurons as well as the globus pallidus, substantia nigra, and brainstem. Understanding of the cellular mechanisms that drive neurodegeneration in HD and account for the characteristic pattern of neuronal vulnerability remains incomplete, but defects in energy metabolism, particularly mitochondrial function, represent a common thread in studies of HD pathogenesis in humans and animal models (7, 8). Here we provide an overview of clinical, biochemical, and molecular evidence of an energy deficit in HD, in both the brain and the peripheral organs. We also discuss the mechanisms underlying mitochondrial and related alterations in the context of both a toxic gain-of-function from mutant Htt and the loss of function of normal Htt (Figure 1). The emerging availability of surrogate markers for clinical trials in HD, i.e., neuroimaging, neurophysiological, and neuropsychiatric changes that may be detectable as early as the presymptomatic stages of the disease (9), should open new avenues for testing promising therapeutic approaches to ameliorate the energy deficit while providing favorable safety profiles.

Normal function of Htt
Despite its identification almost two decades ago, understanding of the normal function of Htt protein is still incomplete. Although mainly found in the cytoplasm, Htt is also present in the nucleus (10, 11). Htt contains a series of up to 36 HEAT, α-helix–loop–α helix, domains that mediate its interaction with numerous proteins involved in gene expression, endocytosis, vesicle trafficking, intracellular signaling, and metabolism (12–14). In particular, the role of Htt in transcription and intracellular transport is well established (15, 16). In the cytoplasm, Htt interacts with the dynein/dynactin complex and kinesin in microtubule-dependent transport of organelles in neurons, including mitochondria (17). For example, WT Htt enhances the vesicular transport of brain derived neurotrophic factor along microtubules (18). Htt may regulate transcription by shuttling transcription factors between the nucleus and the cytoplasm and by interacting with spliceosome-related proteins (19). Studies in Htt knockout mice have shown that Htt is required for normal embryonic development and neurogenesis (20). Interestingly, expression of Htt is also essential for normal development in zebrafish because knock-down by antisense morpholino oligonucleotides leads to multiple developmental abnormalities, including defects in cellular iron trafficking (21), which supports previous in vitro findings that Htt may be regulated by iron levels (22). Recently, it was shown that Htt also plays a role in dividing cells through the regulation of spindle orientation during mitosis together with dynein/dynactin (23).

Pathophysiology of HD
Knockout of Htt is lethal in the mouse early in embryogenesis (24). Reduced Htt levels in knockout embryonic stem cells induce an abnormal distribution and morphology of organelles such as the endoplasmic reticulum, Golgi, and mitochondria (22). In addition, conditional Htt deletion in forebrain neurons at late embryonic or...
early neonatal stages leads to a rapidly progressive neurodegenerative phenotype (25). Reduced Htt levels have been shown to sensitize neurons to the toxic effect of mutant Htt (26). Moreover, increased expression of WT Htt in transgenic mice protected neurons from cell death (27). Similarly, increased expression of WT Htt reduced toxicity in peripheral cells overexpressing mutant Htt (28). Thus, these data indicate that a loss-of-function mechanism likely contributes to HD pathogenesis (29).

Nonetheless, cell and animal model systems as well as the direct correlation between length of CAG repeat and onset of HD strongly support the view that mutant HTT also possesses a new toxic gain of function (30). Like many neurodegenerative diseases, HD is characterized by a cascade of events leading to neuronal cell death. While the sequence of these events remains unclear, several mechanisms implicate energy defects. These include transcriptional dysregulation, changes in axonal transport, excitotoxicity, signaling dysfunction, and neuronal aggregates (31). Here we focus on the role of mitochondrial dysfunction and altered energy metabolism secondary to mechanisms such as impaired trafficking and transcriptional interference (12, 15).

**Figure 1**
Summary figure indicating the main putative mechanisms by which mutated Htt causes mitochondrial dysfunction. Such mechanisms would result in decreased mitochondrial biogenesis, oxidative stress, ATP deficit, increased apoptosis, and, ultimately, a central and peripheral energy deficit. Energy-related therapeutic approaches that have been used in preclinical models and/or HD patients include (i) coenzyme Q10, (ii) creatine, (iii) antioxidant therapies, (iv) anaplerotic therapies, and (v) PPAR agonists. Potential therapeutic targets are also shown, i.e., (vi) calcium homeostasis and (vii) mitochondrial transport. Apaf-1, apoptotic protease activating factor 1; NMDAR, N-Methyl-D-aspartic acid receptor; VDAC, voltage-dependent anion channel.
increased lactate concentrations in the basal ganglia and the occipital cortex of HD patients (36, 37) as well as an elevated lactate-to-pyruvate ratio in the CSF (38). Interestingly, reduced ATP synthesis was found in immunolabeled HD striatal neuronal cell lines (39). However, ATP depletion was directly demonstrated in HD brain tissues only recently by employing a microwave fixation system that instantly inactivates brain enzymes in rodents to preserve in vivo levels of metabolites such as ATP and phosphocreatine (40). Various mechanisms that underlie the energy deficit in HD brain have been proposed, including impaired oxidative phosphorylation (41), oxidative stress (42), impaired mitochondrial calcium handling (43), abnormal mitochondria trafficking (44), deregulation of key factors of mitochondrial biogenesis, such as the transcriptional coactivator PPARγ coactivator-1α (PGC-1α) (45), and decreased glycolysis (46). Furthermore, experimental evidence supports the view that excitatory glutamnergic inputs, which activate NMDA receptors in vulnerable medium spiny neurons, promote cell death by increasing energy demand in the setting of impaired energy capacity (47).

Energy deficit in HD: not only in the brain. The existence of an peripheral energy deficit in HD is an attractive hypothesis because it suggests that clues to the disease pathogenesis may be detectable outside the brain (48). A peripheral mitochondrial defect is suggested by the observation that the ATP/ADP ratio in HD patient–derived lymphoblastoid cell lines is low, which mirrors the findings in striatal cells that contain a full-length mutant Htt (49). Furthermore, the ATP/ADP ratio in lymphoblasts is inversely correlated with the length of the mutant polyglutamine tract, implying an increasingly severe limitation in mitochondrial ATP production with the polyglutamine expansion (49). Skeletal muscle, another differentiated excitable cell type with high metabolic demand, shows energetic disturbances in HD patients similar to those evident in HD striatal neurons (50, 51). Studies utilizing 1H-nuclear magnetic resonance spectroscopy (NMRS) have also revealed a reduced phosphocreatine/inorganic phosphate ratio and low ATP levels in resting muscle of symptomatic HD patients and presymptomatic individuals (52, 53). These findings raise the possibility that the ubiquitous expression of mutant Htt may place other cell types at risk, particularly those with high metabolic demand. Notably, it was found that R6/2 mice, the most commonly used model of HD that contains a microinjected fragment from the 5’ end of the human HTT gene isolated from a phage genomic clone derived from an HD patient, develop cardiac dysfunction by 8 weeks of age, progressing to severe failure at 12 weeks (54). Moreover, weight loss has long been recognized in symptomatic HD patients (55) and is not explained by decreased food intake (56, 57), higher sedentary energy expenditure (58), or involuntary movements (59). Instead, there is evidence for an early hypermetabolic state in HD (60), in which weight loss is associated with a systemic metabolic defect at the presymptomatic stages of the disease. These findings of increased metabolic rate in HD were confirmed in several studies in patients (61, 62) and in mouse models (63, 64). Hypothalamic dysfunction has been suggested to contribute to the negative energy balance in HD through the deregulation of the ghrelin/leptin/orexin system (65–67). Mutated Htt may exert direct deleterious effects on the metabolism of other peripheral organs. A deregulation of adipose tissue metabolism in HD models involves transcriptional interference with PGC-1α (67). In addition, the brain is entirely dependent on energy substrates provided by peripheral organs, so it is conceivable that early weight loss reflects the activation of compensatory mechanisms in peripheral organs in order to provide energetic substrates for a chronic brain energy deficit in HD (60). The slower disease progression in patients exhibiting a higher BMI at presentation supports this hypothesis (68).

Biochemical evidence of energy dysfunction in HD

Is oxidative phosphorylation deficient in HD? Deficiency of respiratory chain complex II, i.e., succinate dehydrogenase (SDH), has been a focus of attention in HD due to the fact that the inhibition of SDH by 3-nitropropionate (3-NP) or malonate has been shown to closely mimic the neuropathology and clinical features of HD in humans, non-human primates (69), and rodents (70). The possible relevance of respiratory chain deficiency to the human disease is supported by postmortem studies of symptomatic patients showing marked deficiency of complexes II and III and lesser deficiency of complex IV in the caudate or putamen, with normal levels in the frontal cortex or cerebellum (71–73). Benchoua and colleagues identified reductions in the 70-kD FAD subunit (SDH A) and the 30-kD iron-sulfur cluster subunit (SDH B) of complex II in HD caudate and putamen that were disproportionate to decreases in the levels of calbindin, a marker of medium spiny neurons, thus implying that complex II subunit depletion preceded neuronal death (74). Furthermore, cultured striatal neurons transfected with a pathogenic N-terminus Htt fragment showed decreased complex II enzymatic activity associated with selective depletion of SDH A and B, and cells were protected from death upon overexpression of complex II/SDH subunits in this model (74).

In a yeast model, a mutant Htt fragment suppressed mitochondrial respiration by suppressing the function of complexes II and III (75). Other cell models of HD have implicated selective deficiency of complex III in cellular pathophysiology (76). However, no significant deficiency of respiratory chain complexes has been demonstrated in presymptomatic patients (77) or in mice expressing full-length mutant Htt (77), suggesting that respiratory chain defects are a secondary feature in the pathogenesis of HD (78). Nevertheless, selective reduction of respiratory chain complexes implies that certain pathophysiological mechanisms target them. One possible mechanism is oxidative stress, to which iron-sulfur cluster–containing proteins, including the SDH B subunit of complex II and the Rieske protein of complex III, are particularly vulnerable (79, 80).

Mitochondria, a source and a target of oxidative stress in HD. Oxidative stress is mediated by increases in ROS including superoxide (O₂⁻), hydrogen peroxide (H₂O₂), hydroxyl radical (OH·), and reactive nitrogen species such as peroxynitrite (ONOO⁻), and ROS impairs cellular function by degrading proteins, lipids, and nucleic acids. Evidence of enhanced oxidative stress in HD brains includes an increase in accumulation of lipofuscin, a product of unsaturated fatty acid peroxidation, that is most prominent in vulnerable striatal neurons (81). Other markers of ROS include strand breaks in DNA and the accumulation of 8-hydroxy-2'-deoxyguanosine (8OHdG) in HD brain and blood (82). Oxidative modification of proteins (protein carbonyls) and lipids (malondialdehyde and 4-hydroxynonenal) are also increased in HD brain and in animal models (83), and increased malondialdehyde is found in blood (84). Another indicator of increased oxidative stress is the finding that oxidative defense mechanisms including mitochondrial and cytoplasmic superoxide dismutase (MnSOD and Cu-Zn SOD, respectively) are induced in HD brains (85) and transgenic animals (86). While the origin of
increased ROS in HD and HD models has not been identified conclusively, the main suspects are mitochondria, where it is estimated that 2 percent of electron flow in the respiratory chain escapes as superoxide, predominantly via complexes I and III. Respiratory chain defects increase ROS production, and complex II inhibition shows that mitochondrial ATP production by uncoupling oxidative phosphorylation may be increased from the observation of selective striatal lesions in the PGC-1α knockout mouse (102). Downregulation of PGC-1α in HD pathogenesis was initially suspected from the observation of selective striatal lesions in the PGC-1α knockout mouse (102). Decreasing levels of PGC-1α were resistant to 3-NP treatment (103). Decreasing levels of PGC-1α were shown to parallel the decrease in levels of Mfn1, a mediator of mitochondrial fusion (98). These results support the view that altered mitochondrial dynamics represent an important mechanism of mitochondrial dysfunction contributing to the mismatch between energy supply and demand that is a recurring theme in HD and HD models.

A possible link between impaired intracellular transport and energy deficit. There are several possible ways in which altered intracellular transport might affect energy metabolism in HD. Full-length mutant Htt may impair mitochondrial motility in mammalian neurons through both a toxic gain of function from the polyglutamine tract and a loss of function of WT Htt (95). Altered mitochondrial trafficking precedes mitochondrial and neuronal abnormalities in both in vitro and in vivo murine models of HD (95). Although aggregates were suspected to impede mitochondrial trafficking (96), N-terminal fragments of mutant Htt alone were later shown to interfere with the association of microtubule-based transport proteins with mitochondria in vitro (97). Mutant Htt altered the distribution and reduced the transport rate of mitochondria together with lowered ATP levels in the synapticosomal fraction isolated from knockin mouse brain (97). However, the mechanisms by which mutant Htt affects intracellular organelle trafficking such as mitochondria are not fully understood (44). A recent study of HD brains identified a reduced number and altered distribution of mitochondria within vulnerable, calbindin-positive striatal neurons that was more pronounced with disease progression (98). Reductions were seen preferentially in large- and medium-size mitochondria in conjunction with an increase in levels of Drp1 protein, a mediator of mitochondrial fission and, with disease progression, a decrease in levels of Mfn1, a mediator of mitochondrial fusion (98). These results support the view that altered mitochondrial dynamics represent an important mechanism of mitochondrial dysfunction contributing to the mismatch between energy supply and demand that is a recurring theme in HD and HD models.

Transcriptional deregulation contributes to altered bioenergetics. Several lines of evidence suggest that transcriptional dysregulation underlies the toxicity of mutant Htt. Whether it is mediated by aggregates, soluble fractions of Htt, or by Htt itself, many transcription factors have been shown to be downregulated in HD. These include CREB-binding protein, TATA-binding protein, and Sp1/TAFII130 (99). Mutant Htt binds the tumor suppression gene p53 more avidly than does WT Htt and has been reported to increase p53 protein levels, nuclear localization, and transcriptional activity in neuronal cultures and transgenic mice (100). Augmented p53 activity was shown to mediate mitochondrial membrane depolarization and a decrease in complex IV activity, as indicated by the fact that p53 inhibition or genetic deletion ameliorated these changes in a cell culture model (100). A specific effect of mutant Htt upon p53 activity is suggested by the fact that p53 activity was not altered by another polyQ-containing protein, ataxin-1 (100). Mutant Htt has also been shown to directly decrease the expression of PGC-1α in the striatum of HD mice and patients through CREB-dependent transcriptional inhibition (45). PGC-1α is a transcriptional coactivator that regulates key energetic metabolic pathways in both brain and peripheral tissues (101). The possible role of PGC-1α in HD pathogenesis was initially suspected from the observation of selective striatal lesions in the PGC-1α knockout mouse (102). Downregulation of PGC-1α in HD striatum was then shown to affect mitochondrial energy metabolism, possibly by impairing oxidative phosphorylation (45). Conversely, HD striatal neurons expressing exogenous PGC-1α were resistant to 3-NP treatment (103). Decreasing levels of PGC-1α were shown to parallel markers of mitochondrial dysfunction with disease progression in HD brains (98). The PPARY agonist rosiglitazone has been shown to increase mitochondrial mass in the striatal cell model of HD and to prevent the decrease in mitochondrial membrane potential and the increase in oxidative stress that otherwise occurs when these cells are challenged with pathogenic increases in intracellular calcium levels.
The hypothesis that there is a deficit of substrates for the TCA cycle in HD patients (104). Of note, PGC-1α polymorphisms in HD patients may account for some variability in symptoms onset (105). In addition, adipose-derived stem cells slowed striatal degeneration and behavioral deterioration of HD models while increasing PGC-1α expression (106). The implication that the PGC-1α dysfunction contributes to HD disease progression is not restricted to the brain (67). Thermoregulatory defects were found in the R6/2 mouse model, associated with impaired activation of brown fat (103). The expression of PGC-1α and its target genes were also decreased in muscle of HD transgenic mice as well as in muscle of HD patients (107).

Although PGC-1α function provides an important link between transcriptional dysregulation and mitochondrial dysfunction in HD, it does not readily explain a selective decrease in respiratory chain proteins such as subunits of SDH/complex II in the pathophysiology of the disease (74). Moreover, mutant Htt may impair cellular bioenergetics by affecting extra-mitochondrial pathways. This was suggested by the dissimilarity of gene expression profiles in the 3-NP models and the HdhQ111/Q111 knockin mouse, in which a gene-targeted replacement of exon 1 of the mouse Hdh with a chimeric mouse/human exon 1 codes for approximately 111 CAG repeats. Whereas both 3-NP and the HD mutation led to impaired energy homeostasis, only 3-NP altered nuclear-encoded mitochondrial gene expression (108).

Therapeutic approaches targeting the energy deficit in HD

As in other neurodegenerative disorders, proven disease-modifying drugs are not yet available in HD, and most therapeutic approaches to improving energetics have aimed at providing substrates designed to slow progression or otherwise compensate for the energy deficit in HD. One such therapy is creatine, which encompasses several potential neuroprotective effects such as buffering intracellular energy pools and stabilizing intracellular calcium concentrations (109). The identification of decreased creatine levels in brain tissues from R6/2 mice (110) encouraged several trials of creatine supplementation in HD mouse models (110–113) despite a lack of overt benefit in HD patients so far (114, 115). Instead, more recent studies in which in vivo concentrations of brain metabolites were preserved by using high-resolution 1H-NMR (116) or enzymatic microwave fixation (40) found increased brain levels of creatine and phosphocreatine in the same mouse model of HD. Moreover, clinical trials of antioxidants designed to slow the progression of the disease have been disappointing. One large-scale study assessing the potential neuroprotective effects of coenzyme Q10, a potential antioxidant and promoter of respiratory chain function, demonstrated a trend toward slowing the decline of the total functional capacity score over 30 months (117) but did not achieve statistical significance. Trials with higher doses are currently ongoing. Other antioxidant approaches were initiated in preclinical models (118, 119) but have not translated into clinical trials. Based on the hypothesis that there is a deficit of substrates for the TCA cycle in HD (60), a short-term therapeutic clinical trial was performed using an anaplerotic compound, triheptanoin, a triglyceride containing seven carbon fatty acids that is metabolized to acetyl-CoA and propionyl-CoA (a precursor of the TCA cycle intermediate, succinate). This study displayed encouraging results for the peripheral metabolism in HD patients, and in particular oxidative phosphorylation in skeletal muscle (120). However, the benefit of anaplerotic approaches for brain energy metabolism remains to be established.

The identification of PGC-1α as a key component of HD pathophysiology supports the use of therapies targeting mitochondrial biogenesis. Activation of the SIRT1 gene family by the polyphenol resveratrol potently induces mitochondrial activity through activating PGC-1α, as evidenced by increased oxidative-type muscle fibers, enhanced resistance to muscle fatigue, and increased tolerance to cold, all PGC-1α-dependent effects (121). Likewise, resveratrol was shown to partially suppress the deleterious effects of mutant polyglutamine in nematode, mouse, and mouse neuronal culture models (122, 123) and significantly reversed 3-NP–induced motor and cognitive impairment (124). In addition, treatments interfering with transcriptional deregulation, such as histone deacetylase inhibitors, were shown to improve mitochondrial dysfunction in striatal neurons from HD mice through the regulation of calcium homeostasis (125). Overall, the multiple functions of Htt in cell metabolism argue for combined therapeutic approaches in order to significantly alter the course of HD and improve energy metabolism, including restoring the normal function of Htt in intracellular transport.

Concluding remarks

Energy deficit is a prominent feature of HD. Energy deficit contributes to the progression of the disease in the brain and can also be traced to the periphery, as reflected in weight loss in HD patients. Importantly, the onset of energy-related manifestations at the presymptomatic stages of the disease, i.e., alterations in brain and muscle metabolism as well as weight loss, underscore the fact that energy deficit is likely to be an early phenomenon in the cascade of events leading to HD pathogenesis. Studies of energy metabolism in HD are therefore worth pursuing to identify potential biomarkers as well as therapeutic targets. Although the data are not entirely concordant, biochemical studies support the view that mitochondrial dysfunction — impaired oxidative phosphorylation, TCA cycle dysfunction, and oxidative stress — is an important determinant of altered energy metabolism in HD. Impaired bioenergetics in HD likely represent downstream effects of both a mutant Htt toxic gain-of-function and a loss-of-function of the WT protein, which, nonetheless, may extend beyond mitochondrial dysfunction. Better understanding of the bioenergetics in HD will more fully illuminate the role of impaired intracellular transport and transcriptional dysregulation in the disease. While treatments designed to improve energy metabolism in the brain and peripheral organs of patients and presymptomatic individuals may not reverse the primary defect in HD on their own, they are likely to significantly alter the course of the disease, delaying disease onset and the pace of disease progression.

Acknowledgments

The authors are grateful to Alexandra Dürr, Sandrine Humbert, and Frédéric Saudou for fruitful discussions.

Address correspondence to: Ronald G. Haller, Department of Neurology, VA Medical Center and University of Texas Southwestern Medical Center and Neuromuscular Center, Institute for Exercise and Environmental Medicine of Presbyterian Hospital, Dallas, Texas 75231, USA. Phone: 214.345.4617; Fax: 214.345.4618; E-mail: Ronald.Haller@UTSouthwestern.edu.

Mitochondria in Huntington’s disease: focusing on huntingtin and the striatum.


Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. 


Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. 


